Company news

Beyondspring, Inc. (NASDAQ:BYSI) news

Beyondspring, Inc. news releases on 6ix. Latest, Sep 29, 2026: BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC…

Beyondspring, Inc. (NASDAQ:BYSI) news

Press releases & updates

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

BeyondSpring : FDA Fast Track designation represents an important regulatory milestone for the Plinabulin and docetaxel combination as an anticancer regimen in…

BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term Value

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

BeyondSpring Announces Poster Presentation at 2026 ASCO Annual Meeting

BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update

BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs

BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026

BeyondSpring Reports 2025 Year-End Financial Results

BeyondSpring Files 2025 Annual Report on Form 10-K

BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path

BeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025

BeyondSpring Reports Third‑Quarter 2025 Financial Results and Provides Corporate Update

BeyondSpring Reports Second‑Quarter 2025 Financial Results and Provides Corporate Update: Accelerates Momentum with Promising Clinical Advances and Strategic Leadership Appointment

BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure

BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting

BeyondSpring Announces Poster Presentation at 2025 ASCO Annual Meeting

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

BeyondSpring Files 2024 Annual Report on Form 10-K

BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones

BeyondSpring : 2024 Full Year Financial Report

BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies

BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respiratory M...

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin

BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics

BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results

BeyondSpring Files 2023 Annual Report on Form 20-F

BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer

BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K

BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement

BeyondSpring Provides Business Update and Reports Year End 2022 Financial Results

BeyondSpring Files 2022 Annual Report on Form 20-F

BeyondSpring Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy

BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical Conferences

BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022

BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting

BeyondSpring Files 2021 Annual Report on Form 20-F

BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update

BeyondSpring Announces Organizational Streamlining

BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update

BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition

BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium

BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)

BeyondSpring Appoints Commercial Leader Mark Santos to its Board of Directors

BeyondSpring Announces First Patient Treated in Phase 2 Study with Plinabulin Combined with Nivolumab + Ipilimumab in Patients in 3rd Line Recurrent Small-Cell Lung Cancer Patients Who Failed Checkpoint Inhibitors